person · Reporting owner

Cadoret-Manier Onaiza

Disclosed activity across 3 companies

Tapewire entity: 36828
SEC CIK: 0001799355

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARDELYX, INC.ARDX · Entity 4972	Director	June 16, 2026	June 18, 2026
IONIS PHARMACEUTICALS INCIONS · Entity 1182	EVP,Chf GL Pdt Str & Oper Ofc	February 02, 2024	September 05, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARDELYX, INC.

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	178,156	Reported balance After 2026-06-16 transaction · row 1 1 source row Row 1 · 2026-06-16 · Grant · Acquired 26,455 · Balance 178,156 F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.67 · Expires 2036-06-16	Direct	39,715	Reported balance After 2026-06-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-16 · Grant · Acquired 39,715 · Balance 39,715 F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program.

F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.

F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.

IONIS PHARMACEUTICALS INC

Report date February 02, 2024 · Filed September 05, 2024 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	35,788	Reported balance After 2024-02-02 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2024-02-02 · Sale · Disposed 2,162 · Balance 35,788 F1: The original Form 4 filed on February 2, 2024 reported 2,125 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Ms. Cadoret-Manier. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.60 to $49.62 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: The original Form 4 filed on February 2, 2024 reported 2,125 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Ms. Cadoret-Manier.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.60 to $49.62 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Ventyx Biosciences, Inc.

Report date March 04, 2026 · Filed March 04, 2026

Section 16 reporting ended · disclosed 2026-03-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.29 · Expires 2034-06-06	Direct	Reported balance After 2026-03-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-03-04 · Disposition to issuer · Disposed 33,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2035-06-05	Direct	Reported balance After 2026-03-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-03-04 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2034-01-21	Direct	Reported balance After 2026-03-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-03-04 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.83 · Expires 2033-06-15	Direct	Reported balance After 2026-03-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-03-04 · Disposition to issuer · Disposed 15,937 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F3: At the Effective Time, this option to purchase shares of the Issuer's common stock was fully vested and had an exercise price per share that was greater than the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2033-01-11	Direct	Reported balance After 2026-03-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-03-04 · Disposition to issuer · Disposed 20,427 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F3: At the Effective Time, this option to purchase shares of the Issuer's common stock was fully vested and had an exercise price per share that was greater than the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent.

F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.

F3: At the Effective Time, this option to purchase shares of the Issuer's common stock was fully vested and had an exercise price per share that was greater than the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 16, 2021 Filed Jun 21, 2021 20:09 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	32,765	$0.00 Strike: $7.31	$0.00	Disclosure SEC source: 0001567619-21-012428 · doc1.xml · derivative · entry 1 Cadoret-Manier Onaiza · CIK 0001799355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,765 Underlying: Common Stock · 32,765 shares Expires 2031-06-16 F1 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document
April 15, 2021 Filed Apr 19, 2021 21:04 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Unit · Derivative	5,667	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-21-000072 · edgardoc.xml · derivative · entry 3 Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 5,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F4 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document
April 15, 2021 Filed Apr 19, 2021 21:04 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Tax withholdingCommon Stock	1,960	$41.03	$80,418.80	Disclosure SEC source: 0000874015-21-000072 · edgardoc.xml · nonDerivative · entry 2 Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,199 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document
April 15, 2021 Filed Apr 19, 2021 21:04 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	5,667	$0.00	$0.00	Disclosure SEC source: 0000874015-21-000072 · edgardoc.xml · nonDerivative · entry 1 Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:27 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	OtherCommon Stock	492	$44.54	$21,913.68	Disclosure SEC source: 0000874015-21-000062 · edgar.xml · nonDerivative · entry 1 Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492 F1 · kind: Reporting 492 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 26, 2021. These 492 shares may not be sold until August 26, 2021. Read SEC document
January 15, 2021 Filed Jan 21, 2021 00:10 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Units · Derivative	24,228	$0.00	$0.00	Disclosure SEC source: 0000874015-21-000043 · edgar.xml · derivative · entry 1 Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,228 Underlying: Common Stock · 24,228 shares Expires not disclosed F1 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document
January 04, 2021 Filed Jan 7, 2021 02:08 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantEmployee Stock Option (right to buy) · Derivative	54,513	$0.00 Strike: $56.78	$0.00	Disclosure SEC source: 0000874015-21-000005 · edgar.xml · derivative · entry 1 Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,513 Underlying: Common Stock · 54,513 shares Expires 2028-01-03 F1 · derivative.exercise_date: Grant on 01/04/2021 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/04/2021. 25% of the shares subject to the option will vest and become exercisable on 01/04/2022. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document
June 09, 2020 Filed Jun 11, 2020 22:38 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	6,155	$0.00	$0.00	Disclosure SEC source: 0001567619-20-012036 · doc1.xml · nonDerivative · entry 1 Cadoret-Manier Onaiza · CIK 0001799355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,155 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document
April 15, 2020 Filed Apr 17, 2020 22:00 UTC Amendment	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Unit · Derivative	22,667	$0.00	$0.00	Disclosure SEC source: 0000874015-20-000068 · edgar.xml · derivative · entry 1 Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,667 Underlying: Common Stock · 22,667 shares Expires not disclosed F1 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · kind: The original Form 4 filed on January 17, 2020 reported Restricted Stock Units granted to the reporting person on January 15, 2020, which has been revised by this amendment to reflect the actual grant date. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document
March 12, 2020 Filed Mar 16, 2020 23:35 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	65,890	$0.00 Strike: $5.23	$0.00	Disclosure SEC source: 0001567619-20-006506 · doc1.xml · derivative · entry 1 Cadoret-Manier Onaiza · CIK 0001799355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,890 Underlying: Common Stock · 65,890 shares Expires 2030-03-12 F1 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 36 successive, equal monthly installments on each monthly anniversary of March 12, 2020, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
January 15, 2020 Filed Jan 17, 2020 23:15 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Units · Derivative	22,667	$0.00	$0.00	Disclosure SEC source: 0000874015-20-000026 · edgar.xml · derivative · entry 1 Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,667 Underlying: Common Stock · 22,667 shares Expires not disclosed F1 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document
January 09, 2020 Filed Jan 14, 2020 00:01 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantEmployee Stock Option (right to buy) · Derivative	51,000	$0.00 Strike: $63.27	$0.00	Disclosure SEC source: 0000874015-20-000022 · edgar.xml · derivative · entry 1 Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2027-01-08 F1 · derivative.exercise_date: Grant on 01/09/2020 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/09/2020. 25% of the shares subject to the option will vest and become exercisable on 01/09/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.